eli lilly glp-1 receptor agonist products Lilly's New Oral Orforglipron Led to 12% Weight Loss in Trials Eli Lilly's $1 Trillion Boom:

doi: 10.1038/s41586-019-1705-2 60 MaoCLiuXZhangYLeiGYanYLeeHet al

The pattern is that both are GI-forward drugs, but retatrutides glucagon activity adds a cardiovascular consideration (heart rate) that cagrilintides amylin mechanism does not, and the same potency that produces retatrutides larger weight loss is associated, in indirect analyses, with a heavier adverse-event load

Who should be cautious: People with cardiovascular concerns, low blood pressure, or who use blood pressure medications or erectile dysfunction medications may be more sensitive to L-arginine and L-citrulline

anti-caking agent - magnesium salts of fatty acids